Laurus Labs Q1 FY27 Revenue Surges 29% to ₹2,026 Crore, EBITDA Up 66%
Laurus Labs reported Q1 FY27 revenue of ₹2,026 Crore, up 29% YoY. EBITDA increased 66% to ₹644 Crore with margins at 31.8%. CDMO revenue grew 67% to ₹870 Crore. CAPEX was ₹394 Crore (19% of sales). R&D increased 74% to ₹118 Crore. The company is investing in Advanced Biologics and has confirmed its SBTi targets.
The significant financial performance, including substantial revenue and profit growth, along with strategic investments in advanced biologics and manufacturing expansion, indicates a high impact on the company's future prospects.
The company reported strong year-on-year growth in revenue, EBITDA, and net profit, along with margin expansion and continued investment in growth initiatives.
Laurus Labs Limited announced its financial results for the quarter ended June 30, 2026, reporting a significant 29% year-on-year increase in revenue to ₹2,026 Crore. The company's EBITDA saw a substantial rise of 66% year-on-year, reaching ₹644 Crore, with EBITDA margins improving by 7.0 percentage points to 31.8%. This strong performance was attributed to robust growth in the CDMO segment, driven by commercial project supplies and steady momentum in the Affordable Medicines segment. Gross margins expanded by 3.3 percentage points to 62.7%, owing to a healthy business segment mix and operational leverage.
The company continued its investment in manufacturing network expansion and niche capabilities, with capital expenditure (CAPEX) at 19% of sales, amounting to ₹394 Crore for the quarter. R&D spending was reported at ₹118 Crore, an increase of 74%, reflecting development efforts in Advanced Biologics infrastructure.
Key business segments showed varied performance: CDMO revenue grew by 67% to ₹870 Crore, primarily from small molecules. The Affordable Medicines segment, including API and FDF, saw a 10% revenue growth to ₹1,156 Crore, with API revenue at ₹654 Crore and FDF revenue at ₹502 Crore.
In the Advanced Biologics division, cell therapy volumes exceeded 660 infusions, and a second GMP production facility in Navi Mumbai became operational. The company has also in-licensed two Antibody-Drug Conjugate (ADC) assets from Aarvik Therapeutics. Laurus Labs reaffirmed its commitment to ESG principles, with a roadmap for GHG reduction and over 50% electricity from renewable sources by 2031.
What to do with a filing like this
Laurus Labs Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Laurus Labs Limited. Read the original for the full detail.